0001237899-13-000010.txt : 20130104 0001237899-13-000010.hdr.sgml : 20130104 20130104100056 ACCESSION NUMBER: 0001237899-13-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130102 FILED AS OF DATE: 20130104 DATE AS OF CHANGE: 20130104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Powchik Peter CENTRAL INDEX KEY: 0001377247 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 13510026 MAIL ADDRESS: STREET 1: REGENERON PHARMACEUTICALS, INC. STREET 2: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2013-01-02 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001377247 Powchik Peter 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 SVP Clin Devel & Reg Affairs Common Stock 2013-01-02 4 M 0 30000.0 21.25 A 44990.0 D Common Stock 2013-01-02 4 F 0 3584.0 177.82 D 41406.0 D Common Stock 2013-01-02 4 F 0 12830.0 177.82 D 28576.0 D Common Stock 2013-01-03 4 S 0 786.0 180.83 D 27790.0 D Common Stock 2013-01-03 4 S 0 6200.0 181.51 D 21590.0 D Common Stock 2013-01-03 4 S 0 2300.0 182.29 D 19290.0 D Common Stock 2013-01-03 4 S 0 4300.0 183.1 D 14990.0 D Common Stock 1532.0 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 21.25 2013-01-02 4 M 0 30000.0 D 2019-12-18 Common Stock 30000.0 295.0 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 786 shares of Company stock on January 3, 2013 at prices ranging from $180.44 to $180.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price. Represents volume-weighted average price of sales of 6,200 shares of Company stock on January 3, 2013 at prices ranging from $181.00 to $181.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price. Represents volume-weighted average price of sales of 2,300 shares of Company stock on January 3, 2013 at prices ranging from $182.03 to $182.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price. Represents volume-weighted average price of sales of 4,300 shares of Company stock on January 3, 2013 at prices ranging from $183.01 to $180.3.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price. The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case. By: Douglas McCorkle For: /s/**Peter Powchik 2013-01-04 EX-24 2 powchik.txt EDGAR SUPPORTING DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Leonard Schleifer, Alicia Pantaleo, Beverly Dubs, Stuart Kolinski, Murray Goldberg, and Douglas McCorkle signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned in the undersigned's capacity as a director of Regeneron Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-act on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of May, 2008. *s/Peter Powchik ---------------- Signature Peter Powchik ------------- Print Name